Published on November 1, 2025, by Bisnis.com
Danantara and SK Plasma are collaborating to build a plasma drug factory in Karawang, reducing imports and increasing Indonesia’s healthcare independence, with completion scheduled for 2026.
By Anggara Pernando
Bisnis.com, JAKARTA – Danantara Indonesia signed a Memorandum of Understanding with South Korean biotechnology company SK Plasma Co Ltd and its subsidiary PT SKPlasma Core Indonesia as part of the efforts to strengthen national health sector. The strategic partnership was meant to reduce Indonesia’s dependence on imported plasma-derived drugs and encourage self-sufficiency in domestic production.
The signing took place in Jakarta on Thursday (31/10). Danantara, the government’s strategic investment management agency, previously designated the healthcare sector as one of its eight investment focuses this year.
Through this collaboration, the two parties will develop a plasma-derived medicinal products (PODP) manufacturing facility in Karawang, West Java, targeted for completion in 2026. Indonesia currently relies on imports for all PODP requirements for patients with rare diseases and critical conditions.
Danantara Indonesia Chief Investment Officer Pandu Sjahrir stated that this collaboration is an important step towards strengthening national health independence.
“One of our investment strategies focuses on strengthening national resilience by reducing dependence on imports, particularly in key sectors such as healthcare. Through the collaboration between SK Plasma’s technical expertise and investment from Danantara Indonesia, we strive to improve the quality of patient care and contribute to saving lives through innovative, globally standardized therapies,” said Pandu Sjahrir in a written statement quoted on Saturday (1/11).
In addition to building production facilities, SK Plasma will also facilitate knowledge transfer through training programs for Indonesian workers in South Korea. This effort is expected to create highly skilled jobs in the biopharmaceutical sector.
Going forward, Danantara will focus on developing healthcare services, manufacturing, and innovation. In addition to the healthcare sector, Danantara, through its investment entities, is also establishing global partnerships to support the industrialization agenda, energy transition, food security, and national infrastructure development.
Following the signing, both parties will continue the review process before executing the investment, in accordance with applicable laws.